NCT04017455View on ClinicalTrials.gov

Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 22, 2019

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Rectal Cancer
Interventions
DRUG

Atezolizumab

3 cycles of atezolizumab 840 mg

DRUG

Bevacizumab

3 cycles of bevacizumab 5mg/kg

Trial Locations (1)

1066CX

Marieke van de Belt, Amsterdam

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER